@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP778526.RAVmRzGcxCUvCnigbx6JgsKL3YSrO9cP1zgpYHCOq9sVI130_head { this: np:hasAssertion dgn-np:NP778526.RAVmRzGcxCUvCnigbx6JgsKL3YSrO9cP1zgpYHCOq9sVI130_assertion; np:hasProvenance dgn-np:NP778526.RAVmRzGcxCUvCnigbx6JgsKL3YSrO9cP1zgpYHCOq9sVI130_provenance; np:hasPublicationInfo dgn-np:NP778526.RAVmRzGcxCUvCnigbx6JgsKL3YSrO9cP1zgpYHCOq9sVI130_publicationInfo; a np:Nanopublication . dgn-np:NP778526.RAVmRzGcxCUvCnigbx6JgsKL3YSrO9cP1zgpYHCOq9sVI130_assertion a np:Assertion . dgn-np:NP778526.RAVmRzGcxCUvCnigbx6JgsKL3YSrO9cP1zgpYHCOq9sVI130_provenance a np:Provenance . dgn-np:NP778526.RAVmRzGcxCUvCnigbx6JgsKL3YSrO9cP1zgpYHCOq9sVI130_publicationInfo a np:PublicationInfo . } dgn-np:NP778526.RAVmRzGcxCUvCnigbx6JgsKL3YSrO9cP1zgpYHCOq9sVI130_assertion { miriam-gene:4751 a ncit:C16612 . lld:C0152013 a ncit:C7057 . dgn-gda:DGN69f932f75d129052e7e55ac466d4fe66 sio:SIO_000628 miriam-gene:4751, lld:C0152013; a sio:SIO_001121 . } dgn-np:NP778526.RAVmRzGcxCUvCnigbx6JgsKL3YSrO9cP1zgpYHCOq9sVI130_provenance { dgn-np:NP778526.RAVmRzGcxCUvCnigbx6JgsKL3YSrO9cP1zgpYHCOq9sVI130_assertion dcterms:description "[SPP1 skeletal development module appears in human normal adjacent tissues (COL11A1_1 activation; COL10A1 inhibition), whereas in lung adenocarcinoma (COL11A1_2, COL1A2 activation); signal module appears in human normal adjacent tissues (COL11A1_1, CXCL13, MMP11, SPINK1 activation; COL10A1, COL3A1 inhibition), whereas in lung adenocarcinoma (COL11A1_2, COL1A2, MMP12 activation; CDH3, CXCL13, GREM1_2, MMP11, SPINK1 inhibition); biological regulation module appears in human normal adjacent tissues (CXCL13, MKI67, PYCR1 activation; NEK2, SPDEF, TOP2A_2, TOX3_1 inhibition), whereas in lung adenocarcinoma (HMGB3, MKI67, NMU, PYCR1, TOX3_2 activation; CXCL13, SPDEF, TOP2A_2 inhibition); sequence variant module appears in human normal adjacent tissues (COL11A1_1, MKI67, MMP11 activation; ASPM, COL10A1, COL3A1, NEK2, TMPRSS4, TOP2A_2 inhibition), whereas in lung adenocarcinoma (COL11A1_2, COL1A2, HMMR, MKI67, MMP12 activation; ABCC3, ASPM, CDH3, MMP11, TOP2A_2 inhibition).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:19949890; prov:wasDerivedFrom dgn-void:befree-2016; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-2016 pav:importedOn "2016-02-19"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP778526.RAVmRzGcxCUvCnigbx6JgsKL3YSrO9cP1zgpYHCOq9sVI130_publicationInfo { this: dcterms:created "2016-05-13T12:47:38+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetv3.0rdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v4.0.0.0" . dgn-void:disgenetv3.0rdf pav:version "v4.0.0" . }